Frontline PET-Directed Therapy with Brentuximab Vedotin Plus AVD Followed By Nivolumab Consolidation in Patients with Limited Stage Hodgkin Lymphoma

Park, Sophie; Ansell, Stephen M.; Giri, Sharmila; Svoboda, Jakub; Smith, Stephen D.; Feldman, Tatyana; Budde, Lihua E.; Ness, Andrew J; Choi, Yunsik; Bierman, Philip J.; Lee, Hun Ju

doi:10.1182/blood-2022-159258

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of standard chemotherapy and novel compounds has also granted interesting results in limited-stage cHL. Park et al [88] tested a new PET-driven treatment scheme in patients with limited-stage, non-bulky cHL composed of three cycles of BV-AVD followed by up to eight cycles of nivolumab. Patients who were still PET-positive at the end of the three BV-AVD cycles received an additional four cycles of BV-N before nivolumab consolidation.…”

Section: Bv-nivolumab Combination and Chemo-free Regimensmentioning

confidence: 99%

Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice

Benevolo Savelli,

Bisio,

Legato

et al. 2024

Cancers

View full text Add to dashboard Cite

Classical Hodgkin Lymphoma (cHL) is a highly curable disease, but around 20% of patients experience progression or relapse after standard frontline chemotherapy regimens. Salvage regimens followed by autologous stem cell transplants represent the historical treatment approach for these cases. In the last decade, with the increasing understanding of cHL biology and tumor microenvironment role in disease course, novel molecules have been introduced in clinical practice, improving outcomes in the relapsed/refractory setting. The anti-CD30 antibody-drug conjugated brentuximab vedotin and PD-1/PD-L1 checkpoint inhibitors represent nowadays curative options for chemorefractory patients, and randomized trials recently demonstrated their efficacy in frontline immune-chemo-combined modalities. Several drugs able to modulate the patients’ T-lymphocytes and NK cell activity are under development, as well as many anti-CD30 chimeric antigen receptor T-cell products. Multiple tumor aberrant epigenetic mechanisms are being investigated as targets for antineoplastic compounds such as histone deacetylase inhibitors and hypomethylating agents. Moreover, JAK2 inhibition combined with anti-PD1 blockade revealed a potential complementary therapeutic pathway in cHL. In this review, we will summarize recent findings on cHL biology and novel treatment options clinically available, as well as promising future perspectives in the field.

show abstract

Section: Bv-nivolumab Combination and Chemo-free Regimensmentioning

confidence: 99%

Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice

Benevolo Savelli,

Bisio,

Legato

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…An impressive percentage of 97% of the patients achieved a negative iPET3 after BV-AVD induction with a CMR rate of 100% at EoT-PET. With a median followup of 22 months, there has been no event of disease progression or death in all eligible patients who received any therapy per the study protocol [90].…”

Section: Brentuximab Vedotin and Checkpoint Inhibitor Combinations In...mentioning

confidence: 99%

Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma

Vassilakopoulos,

Liaskas,

Pereyra

et al. 2023

IJMS

View full text Add to dashboard Cite

The long-term survival of Hodgkin lymphoma (HL) patients treated according to the current standard of care is excellent. Combined-modality schedules (ABVD plus radiotherapy) in early-stage disease, along with treatment intensity adaptation to early metabolic response assessed by PET/CT in advanced stage HL, have been the cornerstones of risk stratification and treatment decision-making, minimizing treatment-related complications while keeping efficacy. Nevertheless, a non-negligible number of patients are primary refractory or relapse after front-line treatment. Novel immunotherapeutic agents, namely Brentuximab Vedotin (BV) and immune checkpoint inhibitors (CPI), have already shown outstanding efficacy in a relapsed/refractory setting in recent landmark studies. Several phase 2 single-arm studies suggest that the addition of these agents in the frontline setting could further improve long-term disease control permitting one to reduce the exposure to cytotoxic drugs. However, a longer follow-up is needed. At the time of this writing, the only randomized phase 3 trial so far published is the ECHELON-1, which compares 1 to 1 BV-AVD (Bleomycin is replaced by BV) with standard ABVD in untreated advanced-stage III and IV HL. The ECHELON-1 trial has proven that BV-AVD is safe and more effective both in terms of long-term disease control and overall survival. Just recently, the results of the S1826 SWOG trial demonstrated that the combination nivolumab-AVD (N-AVD) is better than BV-AVD, while preliminary results of other randomized ongoing phase 3 trials incorporating anti-PD-1 in this setting will be soon available. The aim of this review is to present the recent data regarding these novel agents in first-line treatment of HL and to highlight current and future trends which will hopefully reshape the overall management of this disease.

show abstract

SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma

Chohan

Ansell

2023

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Frontline PET-Directed Therapy with Brentuximab Vedotin Plus AVD Followed By Nivolumab Consolidation in Patients with Limited Stage Hodgkin Lymphoma

Cited by 5 publications

References 0 publications

Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice

Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice

Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma

SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma

Contact Info

Product

Resources

About